Addex Therapeutics SA, of Geneva, said results from its phase IIa study of dipraglurant in levodopa-induced dyskinesia associated with Parkinson's disease, published in Movement Disorders, suggested that the mGluR5 negative allosteric modulator improved dyskinesia and showed no major safety concerns.